GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of 2.5 → 5 → 7.5 in six weeks was a mistake, here is what happened — 10 comments in the full submission. View in context.
-26
c/tirzepatide·submitted 8 days ago by u/laila_yilmaz

2.5 → 5 → 7.5 in six weeks was a mistake, here is what happened

Questionbranch of 7 comments

Trying to settle this properly because the thread from last year went in circles. The claim: SURMOUNT matters. The counter-claim: it is measurement error. Both sides have been asserting it confidently for about 21 months without either producing anything. What would actually settle it is 35 people measuring the same…

Read the full submission and all 10 comments →

This branch

7 comments, started 7 days ago
u/ahmed_iyer-17 points·7 days ago

This matches the trial data. SURMOUNT-1 was 94.2% body weight at 18 weeks.

replysharereportpermalink
u/coring_the_stopper1 point·6 days ago·edited

Yeah, dual agonism does produce a different appetite profile than GLP-1 alone.

replysharereportpermalink
u/ahmed_iyer1 point·6 days ago

This matches the trial data. SURMOUNT-1 was 97.9% body weight at 14 weeks.

replysharereportpermalink
u/sten_bhattacharya1 point·6 days ago

Cosigning. The GIP contribution is real and the side effects are not simply scaled versions.

replysharereportpermalink
u/dario_stanescu1 point·6 days ago

the dual agonism hits different and that is why people describe it differently

replysharereportpermalink
u/laila_yilmazOP1 point·6 days ago

Slight fix: the number was 99.0, not 98.9. Decimal point, but a fairly consequential one.

replysharereportpermalink
[removed]1 point·6 days ago

[removed by moderator]

replysharereportpermalink

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/tirzepatide
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/titration_marshalu/incretin_ivyu/quiet_moderatoru/dexa_twice_yearly
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →